Sign In

Satellite Symposia

  • Open to all meeting registrants
  • These programs are not affiliated with AASLD

AASLD provides an opportunity for registrants at The Liver Meeting® to attend independent symposia financially supported by the pharmaceutical industry. These symposia will take place following The Liver Meeting®'s scheduled educational events on Saturday, November 10 after 7:30 pm; and Sunday, November 11 and Monday, November 12 after 6:30 pm.

Each of the symposia organizers has made a financial contribution in support of the educational mission of AASLD. This support allows symposia organizers access to The Liver Meeting®'s attendees before the meeting by way of mail promotions and on specific evenings during the meeting following official AASLD functions. They also make many features of The Liver Meeting® possible and help maintain reasonable registration fees.

This support is gratefully acknowledged. This acknowledgement, however, does not constitute an endorsement of any product, nor AASLD oversight or endorsement of the content of the program. These programs are not affiliated with AASLD.

Please visit the satellite symposia information center located on the lower level at the Moscone North and South Convention Center for more information and to register for any of the following events.


Saturday, November 10 -- 7:30 pm

Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes

Supported by: Bayer Healthcare Pharmaceuticals Inc., Bristol-Myers Squibb, Eisai Inc., and Exelixis, Inc.
Organized by: PVI, PeerView Institute for Medical Education
CME provided by: Medical Learning Institute, Inc.
Location: Marriott Marquis San Francisco – Golden Gate AB

On completion of this activity, participants should be able to:

  • Assess the benefits and limitations of locoregional therapies in the management of HCC
  • Describe evidence on approved and emerging targeted and immune-oncology therapeutic options in the treatment landscape for HCC
  • Employ effective strategies to monitor and manage the unique adverse effects associated with both targeted and immune-oncology systemic therapies for HCC
  • Utilize collaborative multidisciplinary approaches to develop evidence-based treatment plans incorporating the latest therapeutic strategies for HCC, including possible clinical trial enrollment

For more information, contact PVI at 1-877-833-6141 or (reference the HCC symposium).

New Insights in Hepatorenal Syndrome: An Update for the Liver Specialist

Supported by: Mallinckrodt
Organized by: Medscape Education
CME provided by: Medscape Education
Location: Marriott Marquis San Francisco – Yerba Buena Ballroom, Salon 8

On completion of this activity, participants should be able to:

  • Greater competence related to
    • Diagnosis of hepatorenal syndrome (HRS)
    • Selecting among treatment options for patients with type 1 HRS
  • Increased knowledge regarding
    • Clinical burden and economic implications of HRS
    • Emerging treatment options for HRS

For more information, contact Charlene Foroutan at

Sunday, November 11 -- 6:30 pm

Clinical Issues in Chronic Liver Disease: Hot Topics in HBV, HCV, and NASH

Supported by: Gilead Sciences, Inc.
Organized by: Integritas Communications
CME provided by: Global Education Group
Location: Marriott Marquis San Francisco – Golden Gate AB

On completion of this activity, participants should be able to:

  • Consider recent trends in HBV epidemiology and treatment to optimize patient identification and management
  • Identify approaches to overcome remaining barriers to HCV elimination
  • Discuss data related to new pharmacologic agents under investigation for the treatment of NASH
  • Evaluate current standards for diagnosis, staging and monitoring in chronic liver disease

For more information, contact Christa Master at 727-637-2945 or email


Monday, November 12 -- 6:30 pm

Evidence-Based Management of Hepatorenal Syndrome type 1

Supported by: Mallinckrodt
Organized by: Consultants in Med Ed
CME provided by: Purdue University College of Pharmacy
Location: Marriott Marquis San Francisco – Golden Gate AB

On completion of this activity, participants should be able to:

  • Define and describe the etiology of portal hypertension and other pathologies leading to vasoconstriction of the renal bed and development of hepatorenal syndrome (HRS)
  • Compare and contrast updated International Club of Ascites (ICA) position statement criteria for diagnosis of HRS type 1 with other guidelines available for diagnosis and staging of acute kidney injury
  • Discuss evidence underlying risks and benefits for different pharmacologic and surgical treatment options for the management of HRS type 1
  • Apply proactive evidence-based pharmacotherapy to patients who both meet all criteria for HRS based on the ICA guidelines, and show rapid SCr elevation

For more information contact Chris Blagden, PhD at 347-345-7497 or


The Hepatitis Elimination Symposium and Workshop

Supported by: AbbVie
Organized by: Chronic Liver Disease Foundation (CLDF)
CME provided by: Annenberg
Location: Marriott Marquis San Francisco – Salon 9

On completion of this activity, participants should be able to:

  • Compare the efficacy and safety of current HCV treatment regimens
  • Employ appropriate evidence-based treatments
  • Differentiate among management approaches for special patient populations

For more information and to register, visit